Developing Breakthrough Therapies for
Rare Inflammatory Diseases
www.CorbusPharma.com
OTCQB: CRBP
Exhibit 99.1

2
Forward-Looking Statements
This presentation contains certain forward-looking statements, including those relating to the Company’s
product development, clinical and regulatory timelines, market opportunity, competitive position, possible or
assumed future results of operations, business strategies, potential growth opportunities and other statements
that are predictive in nature.
Additional written and oral forward-looking statements may be made by the
Company from time to time in filings with the Securities and Exchange Commission (SEC) or otherwise.
The
Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements.
These statements may be identified by the use of forward-looking expressions, including, but not limited to,
“expect,”
“anticipate,”
“intend,”
“plan,”
“believe,”
“estimate,”
“potential,”
“predict,”
“project,”
“should,”
“would,”
“will”
and similar expressions and the negatives of those terms.
These statements involve known and unknown
risks, uncertainties, and other factors which may cause actual results, performance or achievements to be
materially different from any future results, performance or achievements expressed or implied by the forward-
looking statements.
Prospective investors are cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this presentation.
The Company undertakes no obligation to
publicly update any forward-looking statement, whether as a result of new information, future events or
otherwise.

3
Overview
•
Corbus Pharma is focusing on rare, life-threatening, chronic inflammatory diseases
•
Lead drug Resunab™:  a first-in-class oral anti-inflammatory/fibrosis small-molecule
•
Acts
to
trigger
inflammatory
resolution:
the
“off”
switch
for
chronic
inflammation
•
Proven safe in Phase 1 + promising pre-clinical potency in multiple animal models
•
Phase 2 clinical trials to commence 2015:
•
Successful $10.3m private financing round (May 2014)
•
Obtained $1.3m in NIH grants
•
IP protection until 2033 and potentially longer
•
Commenced trading on OTCQB in October 2014
•
Cystic Fibrosis (CF)
•
Systemic Sclerosis (SSc) also known as “Scleroderma”

Our Target Indications: Current & Future
Indication
Patient numbers
(USA)
Estimated
Market size
Current therapies
for inflammation
Drawbacks to current
therapies
Current lead indications:
Cystic Fibrosis
30,000
>$3B
Steroids, ibuprofen
Considerable side effects
Diffuse Systemic
Sclerosis
(Scleroderma)
50,000
>$2B
Steroids,
methotrexate
Side effects, poor efficacy
Potential future indications:
Dermatomyositis
13,000
>$1B
Steroids, mAbs
Side effects, poor efficacy
Lupus (SLE)
500,000-1.5MM
>$3B
Steroids, mAbs
Side effects, poor efficacy
Idiopathic
Pulmonary Fibrosis
(IPF)
70,000
>$1B
Pirfenidone
Limited
efficacy
InterMune bought by Roche
for $8.5B (2014)
4

Inflammation
“ON”
Pro-inflammatory
Mediators
(IL6, IL8, PGE2,
LTB4)
Immune cell
TGF-ß
CB2 receptor
Inflammation
“OFF”
Fibrosis
“ON”
Fibrosis
“OFF”
•
CB2 receptor is present on immune cells and activated by endogenous lipid mediators
•
Activation of CB2 turns inflammation off (“inflammatory resolution”)
•
Resunab expected to be first CB2-binding anti-inflammatory drug to reach market
•
Upstream of other approaches: potential for better safety and potency
CB2 Receptor: Turns inflammation “off”
Immune cell
COX
LOX
LXA
4
Anti-
inflammatory
Mediators
(Lipoxins, Resolvins,
etc)
5

6

7
Resunab
7
•
Resunab: synthetic oral CB2
agonist
small-molecule
•
Designed to trigger the resolution of chronic inflammation
•
Full manufacturing, drug supply, non-clinical safety & pharmacology package for Phase 2
programs
•
Excellent clinical safety profile to date: two prior Phase 1 clinical trials (n=123)
•
Preparing to launch two Phase 2 clinical studies in H1 2015

8
Resunab:
Only
CB2-Agonist
Targeting
Inflammation
Company
Indication
Brain penetration
Status
Affects CNS
Corbus Pharma
Inflammation
Minimal
Entering
Phase 2
No
AbbVie
Pain
Full
Phase 1
Yes
Glenmark
Pain
Full
Phase 1
Yes
Eli Lilly
Knee pain
Full
Phase 2
Yes
AstraZeneca
Post operative pain
Full
Phase 2
Yes
Resunab is the only CB2 drug that can be used to treat
inflammation because it does not target the brain

9
Cystic Fibrosis
Targeting inflammation at the core of the disease
9

10
Antibiotics
Kalydeco
(for 6%) of
patients
Very limited 
treatment
No treatment
Overview: Cystic Fibrosis
10
•
Orphan
disease
(30,000
patients
in
USA,
75,000
WW)
•
Average life expectancy of CF patients is approximately 40 years
•
Inflammation at core of disease’s morbidity and mortality (pulmonary fibrosis)
•
Very high doses of steroids/ibuprofen effective but rarely used due to toxicity
•
Need for safe, chronic anti-inflammatory drug is unmet and universally recognized
•
Pharmacoeconomics support premium pricing (e.g. Kalydeco by Vertex priced at $320,000/yr)
CFTR gene
defect
Underlying
Inflammation
Infection
Fibrosis

11
Antibiotics
Kalydeco
(for 6%)
Resunab
Resunab
Resunab
targets key CF inflammatory players
11
TGF-ß
Lipoxin-A4
•
Genetically linked to disease
•
Associated with worsening symptoms
•
Absent in CF lungs
•
CFTR  defect
Underlying
Inflammation
Infection
Fibrosis
Replacement therapy effective in       
animal models

Fibrosis-inducing agent (Bleomycin) administered to lungs
day 1 followed  by daily oral Resunab for 21 days 
P<.004
Bleomycin+
Resunab
therapy
Bleomycin
Control
Gonzales et.al., Annals of Rheumatic Diseases, 2012. 71:1545-51
* Measured by hydroxyproline
Alveoli -air sacs
Resunab
Reduces Pulmonary
Fibrosis In Animal Models
Control
Bleomycin
Bleomycin
+
Resunab
(1mg/kg)
12
0
50
100
150
200
250
300
350

Resunab
Planned Cystic Fibrosis Phase 2 Trial
13
Double blind randomized placebo control study in the US and EU
Primary
endpoints:
Safety/tolerability
Secondary
endpoints:
Pharmacokinetics
and
efficacy
(FEV1,
Lung
Clearance
Index,
CFQ-R
Respiratory
Domain)
Exploratory
endpoints:
Metabolipidomic
profile
for
MOA,
biomarkers
of
disease
activity
in
blood
and
sputum,
biomarkers of inflammation, and microbiota in the lungs
Patient
number:
70
adults
with
CF
in
~20
sites
US
&
EU
Treatment
duration:
3
months
+
1
month
follow-up
Dose
response:
1
mg/day,
5
mg/day,
20
mg/day
and
2x20
mg/day
Q1 2015
Q2 2015
Q3 2015
Q4 2015
Q1 2016
Q2 2016
Q3 2016
Q4 2016
Protocol filed with FDA
X
Study launches
X
First patient dosed
X
Study duration
X
X
X
X
X
X
Last patient dosed
X
Study data released
X

Diffuse Systemic
Sclerosis
(“Scleroderma”)
Relief for a disease with no
effective long-term therapy
14

Overview: Diffuse Cutaneous Systemic Sclerosis
(Scleroderma)
15
•
Chronic inflammatory disease causing fibrosis of skin, joints and internal organs
•
Orphan disease (50,000 patients in USA)
•
80% of patients are women in their 40’s, 50’s and 60’s
•
Common cause of death: lung fibrosis (50% mortality in 10 years)
•
Early stage of disease responds to steroids/methotrexate but with serious side effects
•
No effective and safe long-term therapy available
•
Pipelines often target Idiopathic Pulmonary Fibrosis (IPF) in conjunction to SSc

Resunab
Inhibits Key Factors in SSc
•
TGF-beta plays key role in SSc progression (same in CF and IPF)
•
Elevated TGF-beta levels associated with disease progression
•
Strong Resunab efficacy data in animal models
•
Resunab
reduces
TGF-beta
and
collagen
in
skin
fibroblasts
from
SSc
patients
TGF-beta
Collagen
Concentration of Resunab
(µM)
Concentration of Resunab (µM)
Healthy skin fibroblasts
Scleroderma patients’
skin
fibroblasts
0
50
100
150
200
250
300
350
400
0
0.1
1
5
10
0
5
10
15
20
25
30
35
40
45
0
0.1
1
5
10
16

Resunab
Inhibits Skin Thickening
In Mouse SSc Model
Gonzales et.al., Annals of Rheumatic Diseases, April 4,
2012
17
Control
Bleomycin
Bleomycin
+
Resunab
Thick skin induced by
Bleomycin
Near normal skin after oral
Resunab
taken once daily
for four weeks
Healthy skin
0
100
200
300
400
500

Resunab:
Planned
SSc
Phase
2
Clinical
Trial
18
•
Double
blind
placebo
control
randomized
study
in
USA
under
IND
from
FDA
•
Primary
end
points:
Safety/tolerability
+
Change
in
clinical
outcomes
(CRISS)
•
Secondary
end
points:
Metabolipodomic
profile
+
biomarkers
of
disease
activity
&
inflammation + quality of life (QOL)
•
Patient
number:
36
adults
with
SSc
with
8-10
US
sites
•
Treatment
duration:
3
months
+
1
month
follow-up
•
Dose
response:
5mg/day,
20mg/day
and
20mg/2Xday
Q1 2015
Q2 2015
Q3 2015
Q4 2015
Q1 2016
Q2 2016
Q3 2016
Q4 2016
Protocol filed with
FDA
X
Study launches
X
First patient dosed
X
Study duration
X
X
X
X
X
X
Last patient dosed
X
Study data released
X

Management Team
19
•
Rheumatologist and immunologist.  Previously held positions in industry: SVP and Head, R&D
for Stiefel a GSK company, VP and Head of Inflammation Clinical Development at UCB and
MedImmune/AstraZeneca, and Director, Medical Affairs, Amgen
•
Former CFO: InVivo (NVIV), Celsion (CLSN), Transport Pharma, Echo Therapeutics (ECTE) &
Anika Therapeutics (ANIK)
•
Key
member
of
project
teams
which
developed
the
following
marketed
drugs:
Taxol®
(Ovarian
Cancer,
2000
peak
sales
of
$1.6B),
Orencia®
(RA,
2013
sales
of
$1.4B),
Rebif®
(MS,
2013
sales
of
$2.59B),
Gonal-F®
(Fertility,
2013
sales
of
$815MM)
•
Former VP USA Research & Operations, EMD Serono; Sr. Investigator, Bristol-Myers Squibb
•
Expertise in developing anti-inflammatory drugs including for CF
•
Co-founder and former President of Celsus Therapeutics (CLTX)
Mark Tepper, Ph.D. - President & Chief Scientific Officer
Yuval Cohen, Ph.D. - Chief Executive Officer
Sean Moran, C.P.A. M.B.A. - Chief Financial Officer
Barbara White, M.D. - Chief Medical Officer

Board of Directors
20
Yuval
Cohen,
Ph.D.
-
Chief
Executive
Officer
Avery W. (Chip) Caitlin
Renu Gupta, M.D.
David Hochman
Amb.
Alan
Holmer
-
Chairman
of
the
Board
•
CFO Celldex Therapeutics (CLDX) since 2000
•
Raised over $415MM financing
•
20 years experience in industry: Repligen (CFO) and Endogen (CFO)
•
25 years of development, regulatory and senior management experience in the biopharm industry
•
Former
CMO
of
Insmed,
a
specialty
CF
company
and
current
advisor
to
the
CEO
•
Former Vice President and Head of US Clinical Research and Development at Novartis (2003-2006)
•
Managing Partner of Orchestra Medical Ventures
•
Over 17 years of venture capital and investment banking experience
•
Former Managing Director of Spencer Trask Ventures, Inc. securing over $420 million in equity capital
•
Former CEO of PhRMA (1996-2005)
•
Over
two
decades
of
public
service
in
Washington,
D.C.
including
Special
Envoy
to
China
(2007-2009)
•
Former board member Inspire Pharma (sold to Merck for $430m in 2011)
•
Chairman of the Board of the Metropolitan Washington, D.C. Chapter of the Cystic Fibrosis Foundation

World Class Scientific Advisors
Sumner
Burstein,
Ph.D.
-
UMass
Medical
School
Professor of Biochemistry and Pharmacology; inventor of Resunab
Michael
Knowles,
M.D.,
Ph.D.
-
UNC
Chapel
Hill
Professor of Pulmonary and Critical Care Medicine
James
Chmiel,
M.D.
-
Case
Western
Reserve
Medical
School
Professor Medicine, National PI on largest ever anti-inflammatory CF study
Robert
Spiera
M.D.
-
Hospital
for
Special
Surgery
NYC
Professor of Medicine, Head of Scleroderma and Vasculitis Center
Daniel
Furst,
M.D.
-
UCLA
School
of
Medicine
Director of UCLA Scleroderma Program
Robert
Zurier,
M.D.
-
UMass
Medical
School
Ex-Chair of Rheumatology
21

Financial Profile
OTCQB: CRBP
22
Stock Ticker:
OTCQB: CRBP
$77,400,000
Market
capitalization
as
of
November 5,
2014
$10,300,000
Raise from successful private placement (Q2 2014) from institutional and retail
base
25,800,000
Common shares outstanding
41,500,000
Fully diluted shares outstanding (including warrants and stock options)
$11,400,000
Available from exercise of callable warrants
NASDAQ
Up-listing  to NASDAQ planned by Q-1 2015
Q1 2015
File IND
with FDA
Q1+Q2
2015
Q1 2015
Plan to
up-list to
NASDAQ
H2 2016
Data from
clinical
trials
2014
2016
Oct 2014
Began
trading on
OTCQB
2015
Launch
clinical
trials

Corbus Poised for Significant Upside
23
Recent Deals
Date
Company
Partner
Type
Drug
Indication
Stage
Up-Front
Deal Total
11/2014
Galecto
BMS
Option to
acquire 
TD139
Idiopathic pulmonary fibrosis
Phase 1
NA
$444M*
8/2014
InterMune
Roche
Acquisition
Esbriet
Idiopathic pulmonary fibrosis
Approved
NA
$8.3B*
9/2013
Galapagos
AbbVie
License
GLPG1837
Mutations in CF patients,
including F508del and G551D
Pre-clinical
$45M*
$405M*
7/2011
Amira
BMS
Acquisition
AM152
Idiopathic pulmonary fibrosis
and systemic sclerosis
Phase 1
$325M*
$475M*
* Figures from company press releases
$405
$444
$450
$8,300
$100
$1,000
$10,000
Galapagos       
(License -
AbbVie)
Galecto                  
(M&A -
BMS)
Amira                     
(M&A -
BMS)
Intermune           
(M&A -
Roche)
Recent Deals in CF and Fibrosis
Pre-Clinical
Phase 1
Phase 3

Potential Value Indicators
24
Recent IPO
Date
Company
Lead Compound
Indication
Stage
Market Cap
9/2014
ProQR
QR-010
Cystic Fibrosis -
RNA repair
Pre-clinical
$284.11M
* Figures from company press releases
** Leerink analyst report
Market Cap of CF
and Fibrosis Focused Companies
$286
$685
$1,347
$5,335
$26,000
$77
30
300
3000
30000
Corbus
ProQR
Insmed
PTC
Intercept
Vertex
Market
Phase 3
PC
Phase 2a
Approved Products
Company
Drug
Indication
Cost per Year
2018 Sales Est.
Vertex
Kalydeco
Cystic Fibrosis -
mutations of CFTR gene: G551D, G1244E,
G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R
$294,000
$1.2B**

Conclusions
•
Lead Product Resunab
is a novel, safe and promisingly potent clinical
stage anti-inflammatory/anti-fibrotic drug which acts to resolve
inflammation
•
Targets multiple rare chronic inflammatory indications
•
Proven safe in two Phase 1 trials
•
Promising potency in multiple pre-clinical inflammatory/fibrotic models
•
Launch two Phase 2 trials in 2015 (Cystic Fibrosis and Scleroderma)
•
Completion of studies in 2016
•
Strong patent portfolio until 2033
25

26
100 River Ridge Drive
Norwood, MA 02062
www.CorbusPharma.com